Anti-Hu CD157 Purified

*Arriga R, Caratelli S, Coppola A, Spagnoli GC, Venditti A, Amadori S, Lanzilli G, Lauro D, Palomba P, Sconocchia T, Del Principe MI, Maurillo L, Buccisano F, Capuani B, Ferrone S, Sconocchia G: Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage. , URL: https://www.ncbi.nlm.nih.gov/pubmed/26655503, *Correia RP, Bento LC, Bortolucci AC, Alexandre AM, Vaz AD, Schimidell D, Pedro EC, Perin FS, Nozawa ST, Mendes CE, Barroso RS, Bacal NS: Technical advances in flow cytometry-based diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria. Einstein (Sao Paulo) . 2016 Jul-Sep;14 (3) :366-373., URL: https://www.ncbi.nlm.nih.gov/pubmed/27759825 , *Sutherland DR, Richards SJ, Ortiz F, Nayyar R, Benko M, Marinov I, Illingworth A: CD71 improves delineation of PNH type III, PNH type II, and normal immature RBCS in patients with paroxysmal nocturnal hemoglobinuria. Cytometry B Clin Cytom. 2019 Nov 8. doi: 10.1002/cyto.b.21853. , URL: https://www.ncbi.nlm.nih.gov/pubmed/31705743, *Sutherland DR, Illingworth A, Marinov I, Ortiz F, Andreasen J, Payne D, Wallace PK, Keeney M: ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 2 - reagent selection and assay optimization for high-sensitivity testing. Cytometry B Clin Cytom. 2018 Jan;94 (1) :23-48., URL: https://www.ncbi.nlm.nih.gov/pubmed/29236353